Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
|Poll|June 19, 2015
Mini Quiz: Dementia
Author(s)Psychiatric Times Editors
What is the most common problem in individuals with dementia?
Advertisement
What is the most common problem in individuals with dementia?
Advertisement
Related to this article
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Improving but Not Feeling It: Anticipatory Anhedonia and Cognition
2
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
3
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5